DOPPELIB

What this means for you

Not registered yet, but its 12 Mar 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99080255

Mark type

Stylized text

Filed

12 Mar 2025

Attorney of record

Jeffrey H. Handelsman

Goods and services

• Class 040 — Treatment of materials: Biomanufacturing for others, namely, contract-based purification of antibodies; Biomanufacturing for others, namely, selection and purification of antibodies; Biomanufacturing for others, namely, selection and purification of proteins; Custom manufacturing of cell lines for laboratory, research and development, or medical purposes; Custom manufacturing of cell lines for antibody production; Custom manufacturing of cell lines; Biomanufacturing for others, namely, biomanufacturing of biological cultured tissues for medical, laboratory, or research and development purposes; Biomanufacturing for others, namely, biomanufacturing of biological cultured tissues; Biomanufacturing for others, namely, contract-based biomanufacturing of biological preparations in the nature of proteins; Processing of biological pharmaceutical preparations for others; Treatment of biological pharmaceutical preparations for others; Biomanufacturing for others, namely, selection and purification of biological preparations in the nature of proteins; Contract-based biomanufacturing in the field of pharmaceuticals; Biomanufacturing for others, namely, selection and purification of pharmaceuticals; Biomanufacturing for others, namely, selection and purification of pharmaceutical preparations; Cryogenic preservation of biological tissues; Custom manufacturing of dietary supplements for humans; Food processing; Dietetic food and drink processing; Preservation of antibodies for scientific and medical research and development
• Class 042 — Scientific and technological services: Product research and development services for others in the fields of proteins, antibodies, microorganisms and cells for medical use and consultancy relating thereto; Quality management services, namely, quality control in the fields of proteins, antibodies, microorganisms and cells for medical use and consultancy relating thereto; Research and development services in the field of antibody development technology; Research and development services in the field of antibody technology; Biomedical research services; Design and development of medical technology; Research and development in the field of biotechnology; Pharmaceutical research and development; Scientific research in the nature of conducting clinical trials for others in the field of pharmaceutical preparations; Scientific research in the nature of conducting clinical trials for others; Technical research services, namely, conducting technical project studies in the field of antibody development technology; Technical research in the field of antibody development technology; Engineering services, particularly technical project planning in the field of antibody development technology; Research and development of new products for others; Design and development of computer software for use with medical technology; Software design and development; Rental of computer software for use with medical technology; Providing temporary use of on-line non-downloadable software for use with medical technology; Providing virtual computer systems through cloud computing; Scientific laboratory services relating to the acquisition, isolation and cultivation of antibodies, namely, antibodies or antibody-producing cells with desired properties from a population of cells that produce various antibodies; Scientific laboratory services relating to the screening, isolation and cultivation of antibodies, namely, antibodies or antibody-producing cells with desired properties from a population of cells that produce various antibodies, or the acquisition of antibodies or antibody-producing cells with desired properties; Provision of cell lines for scientific and medical research and development; Provision of antibodies for scientific and medical research and development

Owner

• CHIOME BIOSCIENCE INC., Tokyo, JP

Prosecution history

• 31 Mar 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
• 31 Mar 2026 — FINAL REFUSAL E-MAILED
• 31 Mar 2026 — FINAL REFUSAL WRITTEN
• 24 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 24 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 24 Feb 2026 — ASSIGNED TO LIE
• 18 Feb 2026 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
• 29 Dec 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
• 29 Dec 2025 — LETTER OF SUSPENSION E-MAILED
• 29 Dec 2025 — SUSPENSION LETTER WRITTEN
• 04 Dec 2025 — PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
• 04 Dec 2025 — TEAS VOLUNTARY AMENDMENT RECEIVED
• 03 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 03 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 03 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED